Investment firm based in Paris and San Francisco, Lauxera Capital Partners announced the final closing of its first fund, Lauxera Growth I, at more than €260 million (approximately $300 million), making it one of the leading European funds dedicated to financing innovative health tech companies.
Lauxera Growth I achieved a first closing in January 2021 of nearly €100 million. The round saw the participation of Covea, Candriam, Bpifrance and French public financial institution Caisse des Dépôts. Major European family offices also participated such as Tethys, Compagnie Nationale à Portefeuille (CNP), Financière Dassault, and Italmobiliare. The new investors that joined the current round include European Investment Fund (EIF), the Biotech Health Acceleration fund (FABS) handled on behalf of the French government by Bpifrance, insurance leaders Matmut and Harmonie Mutuelle (Vyv Group), and Swen Capital Partners.
Launched in January 2021, Lauxera Growth I exceeded its initial fundraising target of €150 million and its initial hard cap of €200 million. The fund’s upsized raise reflects the rise in investment opportunities in the fast-growing European health tech companies. Investing up to €20-40 million in each company, it makes minority growth and majority growth buyout investments to help founders drive international commercialisation, particularly in the U.S. market.
Among its first five investments, Lauxera Growth I acted as lead or co-lead investor in the latest financing rounds of Reapplix (Denmark), LUMICKS (Netherlands), Caresyntax (Germany & U.S.), and Lifen (France), and led the acquisition of a majority stake in Groupe PSIH (France).
Pierre Moustial, Chairman and Co-founder of Lauxera Capital Partners said: "The size and the quality of our limited partners allow us to operate at the same level as the largest American specialist funds financing health tech innovators with global ambitions. We can accelerate the international growth of our portfolio companies and transform them into multi-national champions in health tech. Over the past year, we have invested close to 25% of the fund's final size in five companies, playing active governance and advisory roles to accelerate their growth.”
Dr. Samuel Levy and Alex Slack, Co-founders of Lauxera Capital Partners, added: "Our vision has been to position our fund as a key player in supporting the scale-up of European health tech companies. As the critical challenge for these companies is to quickly penetrate the U.S. market, our network, our regulatory and commercial skills, and our transatlantic positioning naturally make us the ideal partner. Europe has an unparalleled wealth of healthcare innovations and an array of great medical technology companies in healthcare software, medical devices, research tools, digital health, and biomanufacturing that can radically improve the efficiency of our healthcare systems while improving outcomes for patients.”